Brokerages Set Geron Corporation (NASDAQ:GERN) Target Price at $2.75

Shares of Geron Corporation (NASDAQ:GERN) have received a consensus recommendation of “Hold” from the seven research firms that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $2.1667.

Several analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Geron in a report on Wednesday, January 28th. Needham & Company LLC reduced their price objective on shares of Geron from $5.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. TD Cowen reaffirmed a “buy” rating on shares of Geron in a report on Thursday, January 29th. HC Wainwright reiterated a “neutral” rating on shares of Geron in a research report on Tuesday, December 9th. Finally, UBS Group reissued a “neutral” rating on shares of Geron in a research note on Tuesday, December 9th.

Institutional Investors Weigh In On Geron

Hedge funds and other institutional investors have recently bought and sold shares of the business. 55 North Private Wealth LLC acquired a new position in shares of Geron during the 4th quarter worth $29,000. LCM Capital Management Inc lifted its stake in shares of Geron by 80.6% in the fourth quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 10,000 shares during the period. Vistica Wealth Advisors LLC purchased a new stake in Geron during the fourth quarter worth about $33,000. Caitong International Asset Management Co. Ltd grew its position in Geron by 3,307.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 24,410 shares during the period. Finally, Swiss Life Asset Management Ltd grew its position in Geron by 73.6% during the third quarter. Swiss Life Asset Management Ltd now owns 26,371 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 11,182 shares during the period. Institutional investors and hedge funds own 73.71% of the company’s stock.

Geron Price Performance

Geron stock opened at $1.44 on Wednesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.96 and a quick ratio of 4.87. The business has a 50 day simple moving average of $1.49 and a 200-day simple moving average of $1.36. Geron has a 12 month low of $1.04 and a 12 month high of $2.01. The stock has a market capitalization of $919.22 million, a PE ratio of -11.08 and a beta of 0.58.

Geron (NASDAQ:GERN) last posted its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.02). The firm had revenue of $48.02 million during the quarter, compared to analysts’ expectations of $50.43 million. Geron had a negative net margin of 46.65% and a negative return on equity of 27.94%. Equities analysts predict that Geron will post -0.25 earnings per share for the current year.

About Geron

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.